hepatocellular carcinoma (HCC)
Conditions
Interventions
Single yttrium-90 treatment group:None
TACE combined with target therapy and timmunotherapy group:None
Single TACE group treatment group:None
Yttrium-90 combined with target therapy and immunotherapy group:None
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Both sexes, aged 18-75 years; 2.Unresectable hepatocellular carcinoma (HCC) confirmed by imaging (CT/MRI) or histology according to Barcelona Clinic Liver Cancer (BCLC) staging system (B /C stage); 3.Previous systemic therapy (such as targeted therapy, immunotherapy, etc.) or surgical treatment; 4.One or more tumor lesions can be measured according to the modified response evaluation criteria in solid tumors (mRECIST) criteria on enhanced CT or MRI; 5.Child-Pugh class A or B, no hydrothorax, ascites or hepatic encephalopathy requiring treatment; 6.Eastern Cooperative Oncology Group performance status (ECOG-PS) score 0-1; 7.Adequate renal function (serum creatinine =133 µmol/L, estimated glomerular filtration rate (eGFR) = 60 mL/min) before treatment; 8.No other related diseases affecting treatment.
Exclusion criteria
Exclusion criteria: 1.Malignant tumors secondary to HCC; 2.Child-Pugh class C, or severe liver dysfunction (e.g., hepatic encephalopathy, persistent bleeding, etc.) that cannot be corrected by treatment; 3.Patients with acute hepatitis or acute exacerbation of liver disease; 4.Patients with severe complications, such as severe heart disease, renal insufficiency, severe diabetes, etc., who cannot tolerate interventional therapy; 5.Severe heart, lung, kidney, and coagulation dysfunction; 6.A history of idiopathic pulmonary fibrosis; 7.Pregnant or lactating women, or other special populations that may affect the study results; 8.Incomplete clinical or follow-up information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Objective response rate;Disease control rate; | — |
Countries
China
Contacts
Public ContactJiayun Jiang
The First Affiliated Hospital of Army Medical University
Outcome results
None listed